Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer.

Petrylak DP, Kantoff P, Vogelzang NJ, Mega A, Fleming MT, Stephenson JJ Jr, Frank R, Shore ND, Dreicer R, McClay EF, Berry WR, Agarwal M, DiPippo VA, Rotshteyn Y, Stambler N, Olson WC, Morris SA, Israel RJ.

Prostate. 2019 May;79(6):604-613. doi: 10.1002/pros.23765. Epub 2019 Jan 20.

PMID:
30663074
2.

Novel small-molecule inhibitors of hepatitis C virus entry block viral spread and promote viral clearance in cell culture.

Coburn GA, Fisch DN, Moorji SM, de Muys JM, Murga JD, Paul D, Provoncha KP, Rotshteyn Y, Han AQ, Qian D, Maddon PJ, Olson WC.

PLoS One. 2012;7(4):e35351. doi: 10.1371/journal.pone.0035351. Epub 2012 Apr 24.

3.

Methylnaltrexone bromide: research update of pharmacokinetics following parenteral administration.

Rotshteyn Y, Boyd TA, Yuan CS.

Expert Opin Drug Metab Toxicol. 2011 Feb;7(2):227-35. doi: 10.1517/17425255.2011.549824. Epub 2011 Jan 11. Review.

PMID:
21222554
4.

Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults.

Jacobson JM, Lalezari JP, Thompson MA, Fichtenbaum CJ, Saag MS, Zingman BS, D'Ambrosio P, Stambler N, Rotshteyn Y, Marozsan AJ, Maddon PJ, Morris SA, Olson WC.

Antimicrob Agents Chemother. 2010 Oct;54(10):4137-42. doi: 10.1128/AAC.00086-10. Epub 2010 Jul 26.

5.

Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody.

Jacobson JM, Thompson MA, Lalezari JP, Saag MS, Zingman BS, D'Ambrosio P, Stambler N, Rotshteyn Y, Marozsan AJ, Maddon PJ, Morris SA, Olson WC.

J Infect Dis. 2010 May 15;201(10):1481-7. doi: 10.1086/652190.

6.

In vitro metabolism and identification of human enzymes involved in the metabolism of methylnaltrexone.

Tong Z, Chandrasekaran A, Li H, Rotshteyn Y, Erve JC, Demaio W, Talaat R, Hultin T, Scatina J.

Drug Metab Dispos. 2010 May;38(5):801-7. doi: 10.1124/dmd.110.032169. Epub 2010 Feb 19.

PMID:
20173089
7.

Metabolism of intravenous methylnaltrexone in mice, rats, dogs, and humans.

Chandrasekaran A, Tong Z, Li H, Erve JC, DeMaio W, Goljer I, McConnell O, Rotshteyn Y, Hultin T, Talaat R, Scatina J.

Drug Metab Dispos. 2010 Apr;38(4):606-16. doi: 10.1124/dmd.109.031179. Epub 2010 Jan 6.

PMID:
20053817
8.

Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults.

Jacobson JM, Saag MS, Thompson MA, Fischl MA, Liporace R, Reichman RC, Redfield RR, Fichtenbaum CJ, Zingman BS, Patel MC, Murga JD, Pemrick SM, D'Ambrosio P, Michael M, Kroger H, Ly H, Rotshteyn Y, Buice R, Morris SA, Stavola JJ, Maddon PJ, Kremer AB, Olson WC.

J Infect Dis. 2008 Nov 1;198(9):1345-52. doi: 10.1086/592169.

PMID:
18771406
9.

Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy.

Valenzano KJ, Tafesse L, Lee G, Harrison JE, Boulet JM, Gottshall SL, Mark L, Pearson MS, Miller W, Shan S, Rabadi L, Rotshteyn Y, Chaffer SM, Turchin PI, Elsemore DA, Toth M, Koetzner L, Whiteside GT.

Neuropharmacology. 2005 Apr;48(5):658-72.

PMID:
15814101
10.

Synthesis and evaluation of pyridazinylpiperazines as vanilloid receptor 1 antagonists.

Tafesse L, Sun Q, Schmid L, Valenzano KJ, Rotshteyn Y, Su X, Kyle DJ.

Bioorg Med Chem Lett. 2004 Nov 15;14(22):5513-9.

PMID:
15482915
11.

Comparison of alamar blue and MTT assays for high through-put screening.

Hamid R, Rotshteyn Y, Rabadi L, Parikh R, Bullock P.

Toxicol In Vitro. 2004 Oct;18(5):703-10.

PMID:
15251189
12.
13.

DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted Mu opioid agonist with antihyperalgesic activity: II. In vivo pharmacological characterization in the rat.

Whiteside GT, Harrison JE, Pearson MS, Chen Z, Fundytus ME, Rotshteyn Y, Turchin PI, Pomonis JD, Mark L, Walker K, Broglé KC.

J Pharmacol Exp Ther. 2004 Aug;310(2):793-9. Epub 2004 Mar 30. Erratum in: J Pharmacol Exp Ther. 2005 Mar;312(3):1334. Fundytus, Marian E [added].

PMID:
15054116
14.

DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted mu opioid agonist with antihyperalgesic activity: I. In vitro pharmacological characterization and pharmacokinetic properties.

Valenzano KJ, Miller W, Chen Z, Shan S, Crumley G, Victory SF, Davies E, Huang JC, Allie N, Nolan SJ, Rotshteyn Y, Kyle DJ, Broglé K.

J Pharmacol Exp Ther. 2004 Aug;310(2):783-92. Epub 2004 Mar 30.

PMID:
15054115
15.

4-(2-pyridyl)piperazine-1-carboxamides: potent vanilloid receptor 1 antagonists.

Sun Q, Tafesse L, Islam K, Zhou X, Victory SF, Zhang C, Hachicha M, Schmid LA, Patel A, Rotshteyn Y, Valenzano KJ, Kyle DJ.

Bioorg Med Chem Lett. 2003 Oct 20;13(20):3611-6.

PMID:
14505681
16.

N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. in vitro characterization and pharmacokinetic properties.

Valenzano KJ, Grant ER, Wu G, Hachicha M, Schmid L, Tafesse L, Sun Q, Rotshteyn Y, Francis J, Limberis J, Malik S, Whittemore ER, Hodges D.

J Pharmacol Exp Ther. 2003 Jul;306(1):377-86. Epub 2003 Apr 29.

PMID:
12721338
17.

Pharmacology of a new cyclic nucleotide phosphodiesterase type 4 inhibitor, V11294.

Gale DD, Hofer P, Spina D, Seeds EA, Banner KH, Harrison S, Douglas G, Matsumoto T, Page CP, Wong RH, Jordan S, Smith F, Banik N, Halushka PV, Cavalla D, Rotshteyn Y, Kyle DJ, Burch RM, Chasin M.

Pulm Pharmacol Ther. 2003;16(2):97-104. Review.

PMID:
12670778
18.

Pharmacokinetic and pharmacodynamic profile following oral administration of the phosphodiesterase (PDE)4 inhibitor V11294A in healthy volunteers.

Gale DD, Landells LJ, Spina D, Miller AJ, Smith K, Nichols T, Rotshteyn Y, Tonelli A, Lacouture P, Burch RM, Page CP, O'Connor BJ.

Br J Clin Pharmacol. 2002 Nov;54(5):478-84.

Supplemental Content

Loading ...
Support Center